Loading…

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Understanding the molecular pathogenesis of lymphoma has led to paradigm-changing treatment opportunities. One example involves tailoring specific agents based on the cell of origin in aggressive lymphomas. Germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL) is known to be driven by a...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2013-09, Vol.122 (12), p.2104-2113
Main Authors: Amengual, Jennifer E., Clark-Garvey, Sean, Kalac, Matko, Scotto, Luigi, Marchi, Enrica, Neylon, Ellen, Johannet, Paul, Wei, Ying, Zain, Jasmine, O'Connor, Owen A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c408t-54be4748bf3661ffda5204008d9fbcf537559ccbffbda8fbd8339c5f6eda52613
cites cdi_FETCH-LOGICAL-c408t-54be4748bf3661ffda5204008d9fbcf537559ccbffbda8fbd8339c5f6eda52613
container_end_page 2113
container_issue 12
container_start_page 2104
container_title Blood
container_volume 122
creator Amengual, Jennifer E.
Clark-Garvey, Sean
Kalac, Matko
Scotto, Luigi
Marchi, Enrica
Neylon, Ellen
Johannet, Paul
Wei, Ying
Zain, Jasmine
O'Connor, Owen A.
description Understanding the molecular pathogenesis of lymphoma has led to paradigm-changing treatment opportunities. One example involves tailoring specific agents based on the cell of origin in aggressive lymphomas. Germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL) is known to be driven by an addiction to Bcl6, whereas the activated B-cell (ABC) subtype is driven by nuclear factor κB. In the GC subtype, there is a critical inverse relationship between Bcl6 and p53, the functional status of which is linked to each transcription factor's degree of acetylation. Deacetylation of Bcl6 is required for its transcriptional repressor effects allowing for the oncogene to drive lymphomagenesis. Conversely, acetylation of p53 is activating when class III deacetylases (DACs), or sirtuins, are inhibited by niacinamide. Treatment of DLBCL cell lines with pan-DAC inhibitors in combination with niacinamide produces synergistic cytotoxicity in GC over ABC subtypes. This correlated with acetylation of both Bcl6 and p53. This combination also produced remissions in a spontaneous aggressive B-cell lymphoma mouse model expressing Bcl6. In a phase 1 proof-of-principle clinical trial, 24% of patients with relapsed or refractory lymphoma attained a response to vorinostat and niacinamide, and 57% experienced disease stabilization. We report herein on the preclinical and clinical activity of this targeted strategy in aggressive lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT00691210. •Treatment of DLBCL with the combination of sirtuin and DAC inhibitors leads to synergistic cytotoxicity and acetylation of Bcl6 and p53.•The overall response rate of relapsed lymphoma patients treated with vorinostat and niacinamide was 24%, and an additional 57% achieved stable disease.
doi_str_mv 10.1182/blood-2013-02-485441
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2013_02_485441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120431490</els_id><sourcerecordid>23913470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-54be4748bf3661ffda5204008d9fbcf537559ccbffbda8fbd8339c5f6eda52613</originalsourceid><addsrcrecordid>eNp9kElLA0EQhRtRNC7_QKSPemhTvU1mLoLELSB4UM9NTy9aMhvTEyEH_7sTozl6qYKq915RHyGnHC45z8W0rNrWMwFcMhBM5VopvkMmXIucAQjYJRMAyJgqZvyAHKb0AcCVFHqfHAhZcKlmMCFfz9gPS2yobTztbMNcZVOii-liQX2wLgyrcRDo-c31_IJi844lDtg2FBNNqyb0b5gGdOOGdn1wFTbobEXr1ocq_YRuZ2lYegyJtpFWq7p7b2t7TPairVI4-e1H5PXu9mX-wB6f7hfz60fmFOQD06oMaqbyMsos4zF6qwUogNwXsXRRy5nWhXNljKW3-VhyKQunYxbWyozLI6I2ua5vU-pDNF2Pte1XhoNZ0zQ_NM2apgFhNjRH29nG1i3LOvit6Q_fKLjaCMZnwyeG3iSHoXHB4whjML7F_y98A_tOiI4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma</title><source>ScienceDirect - Connect here FIRST to enable access</source><creator>Amengual, Jennifer E. ; Clark-Garvey, Sean ; Kalac, Matko ; Scotto, Luigi ; Marchi, Enrica ; Neylon, Ellen ; Johannet, Paul ; Wei, Ying ; Zain, Jasmine ; O'Connor, Owen A.</creator><creatorcontrib>Amengual, Jennifer E. ; Clark-Garvey, Sean ; Kalac, Matko ; Scotto, Luigi ; Marchi, Enrica ; Neylon, Ellen ; Johannet, Paul ; Wei, Ying ; Zain, Jasmine ; O'Connor, Owen A.</creatorcontrib><description>Understanding the molecular pathogenesis of lymphoma has led to paradigm-changing treatment opportunities. One example involves tailoring specific agents based on the cell of origin in aggressive lymphomas. Germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL) is known to be driven by an addiction to Bcl6, whereas the activated B-cell (ABC) subtype is driven by nuclear factor κB. In the GC subtype, there is a critical inverse relationship between Bcl6 and p53, the functional status of which is linked to each transcription factor's degree of acetylation. Deacetylation of Bcl6 is required for its transcriptional repressor effects allowing for the oncogene to drive lymphomagenesis. Conversely, acetylation of p53 is activating when class III deacetylases (DACs), or sirtuins, are inhibited by niacinamide. Treatment of DLBCL cell lines with pan-DAC inhibitors in combination with niacinamide produces synergistic cytotoxicity in GC over ABC subtypes. This correlated with acetylation of both Bcl6 and p53. This combination also produced remissions in a spontaneous aggressive B-cell lymphoma mouse model expressing Bcl6. In a phase 1 proof-of-principle clinical trial, 24% of patients with relapsed or refractory lymphoma attained a response to vorinostat and niacinamide, and 57% experienced disease stabilization. We report herein on the preclinical and clinical activity of this targeted strategy in aggressive lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT00691210. •Treatment of DLBCL with the combination of sirtuin and DAC inhibitors leads to synergistic cytotoxicity and acetylation of Bcl6 and p53.•The overall response rate of relapsed lymphoma patients treated with vorinostat and niacinamide was 24%, and an additional 57% achieved stable disease.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2013-02-485441</identifier><identifier>PMID: 23913470</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acetylation - drug effects ; Adult ; Aged ; Animals ; Cell Line, Tumor ; Cell Survival - drug effects ; Disease Models, Animal ; Drug Evaluation, Preclinical ; Drug Synergism ; Female ; Histone Deacetylase Inhibitors - adverse effects ; Histone Deacetylase Inhibitors - pharmacology ; Histone Deacetylase Inhibitors - therapeutic use ; Histone Deacetylases - metabolism ; Humans ; Inhibitory Concentration 50 ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - metabolism ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; Mice ; Middle Aged ; Niacinamide - adverse effects ; Niacinamide - pharmacology ; Niacinamide - therapeutic use ; Proto-Oncogene Proteins - metabolism ; Repressor Proteins - metabolism ; Sirtuins - metabolism ; Treatment Outcome ; Tumor Burden - drug effects ; Tumor Suppressor Protein p53 - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>Blood, 2013-09, Vol.122 (12), p.2104-2113</ispartof><rights>2013 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-54be4748bf3661ffda5204008d9fbcf537559ccbffbda8fbd8339c5f6eda52613</citedby><cites>FETCH-LOGICAL-c408t-54be4748bf3661ffda5204008d9fbcf537559ccbffbda8fbd8339c5f6eda52613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006497120431490$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23913470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amengual, Jennifer E.</creatorcontrib><creatorcontrib>Clark-Garvey, Sean</creatorcontrib><creatorcontrib>Kalac, Matko</creatorcontrib><creatorcontrib>Scotto, Luigi</creatorcontrib><creatorcontrib>Marchi, Enrica</creatorcontrib><creatorcontrib>Neylon, Ellen</creatorcontrib><creatorcontrib>Johannet, Paul</creatorcontrib><creatorcontrib>Wei, Ying</creatorcontrib><creatorcontrib>Zain, Jasmine</creatorcontrib><creatorcontrib>O'Connor, Owen A.</creatorcontrib><title>Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma</title><title>Blood</title><addtitle>Blood</addtitle><description>Understanding the molecular pathogenesis of lymphoma has led to paradigm-changing treatment opportunities. One example involves tailoring specific agents based on the cell of origin in aggressive lymphomas. Germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL) is known to be driven by an addiction to Bcl6, whereas the activated B-cell (ABC) subtype is driven by nuclear factor κB. In the GC subtype, there is a critical inverse relationship between Bcl6 and p53, the functional status of which is linked to each transcription factor's degree of acetylation. Deacetylation of Bcl6 is required for its transcriptional repressor effects allowing for the oncogene to drive lymphomagenesis. Conversely, acetylation of p53 is activating when class III deacetylases (DACs), or sirtuins, are inhibited by niacinamide. Treatment of DLBCL cell lines with pan-DAC inhibitors in combination with niacinamide produces synergistic cytotoxicity in GC over ABC subtypes. This correlated with acetylation of both Bcl6 and p53. This combination also produced remissions in a spontaneous aggressive B-cell lymphoma mouse model expressing Bcl6. In a phase 1 proof-of-principle clinical trial, 24% of patients with relapsed or refractory lymphoma attained a response to vorinostat and niacinamide, and 57% experienced disease stabilization. We report herein on the preclinical and clinical activity of this targeted strategy in aggressive lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT00691210. •Treatment of DLBCL with the combination of sirtuin and DAC inhibitors leads to synergistic cytotoxicity and acetylation of Bcl6 and p53.•The overall response rate of relapsed lymphoma patients treated with vorinostat and niacinamide was 24%, and an additional 57% achieved stable disease.</description><subject>Acetylation - drug effects</subject><subject>Adult</subject><subject>Aged</subject><subject>Animals</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Disease Models, Animal</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Synergism</subject><subject>Female</subject><subject>Histone Deacetylase Inhibitors - adverse effects</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Histone Deacetylase Inhibitors - therapeutic use</subject><subject>Histone Deacetylases - metabolism</subject><subject>Humans</subject><subject>Inhibitory Concentration 50</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - metabolism</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Middle Aged</subject><subject>Niacinamide - adverse effects</subject><subject>Niacinamide - pharmacology</subject><subject>Niacinamide - therapeutic use</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>Repressor Proteins - metabolism</subject><subject>Sirtuins - metabolism</subject><subject>Treatment Outcome</subject><subject>Tumor Burden - drug effects</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kElLA0EQhRtRNC7_QKSPemhTvU1mLoLELSB4UM9NTy9aMhvTEyEH_7sTozl6qYKq915RHyGnHC45z8W0rNrWMwFcMhBM5VopvkMmXIucAQjYJRMAyJgqZvyAHKb0AcCVFHqfHAhZcKlmMCFfz9gPS2yobTztbMNcZVOii-liQX2wLgyrcRDo-c31_IJi844lDtg2FBNNqyb0b5gGdOOGdn1wFTbobEXr1ocq_YRuZ2lYegyJtpFWq7p7b2t7TPairVI4-e1H5PXu9mX-wB6f7hfz60fmFOQD06oMaqbyMsos4zF6qwUogNwXsXRRy5nWhXNljKW3-VhyKQunYxbWyozLI6I2ua5vU-pDNF2Pte1XhoNZ0zQ_NM2apgFhNjRH29nG1i3LOvit6Q_fKLjaCMZnwyeG3iSHoXHB4whjML7F_y98A_tOiI4</recordid><startdate>20130919</startdate><enddate>20130919</enddate><creator>Amengual, Jennifer E.</creator><creator>Clark-Garvey, Sean</creator><creator>Kalac, Matko</creator><creator>Scotto, Luigi</creator><creator>Marchi, Enrica</creator><creator>Neylon, Ellen</creator><creator>Johannet, Paul</creator><creator>Wei, Ying</creator><creator>Zain, Jasmine</creator><creator>O'Connor, Owen A.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20130919</creationdate><title>Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma</title><author>Amengual, Jennifer E. ; Clark-Garvey, Sean ; Kalac, Matko ; Scotto, Luigi ; Marchi, Enrica ; Neylon, Ellen ; Johannet, Paul ; Wei, Ying ; Zain, Jasmine ; O'Connor, Owen A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-54be4748bf3661ffda5204008d9fbcf537559ccbffbda8fbd8339c5f6eda52613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acetylation - drug effects</topic><topic>Adult</topic><topic>Aged</topic><topic>Animals</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Disease Models, Animal</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Synergism</topic><topic>Female</topic><topic>Histone Deacetylase Inhibitors - adverse effects</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Histone Deacetylase Inhibitors - therapeutic use</topic><topic>Histone Deacetylases - metabolism</topic><topic>Humans</topic><topic>Inhibitory Concentration 50</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - metabolism</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Middle Aged</topic><topic>Niacinamide - adverse effects</topic><topic>Niacinamide - pharmacology</topic><topic>Niacinamide - therapeutic use</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>Repressor Proteins - metabolism</topic><topic>Sirtuins - metabolism</topic><topic>Treatment Outcome</topic><topic>Tumor Burden - drug effects</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amengual, Jennifer E.</creatorcontrib><creatorcontrib>Clark-Garvey, Sean</creatorcontrib><creatorcontrib>Kalac, Matko</creatorcontrib><creatorcontrib>Scotto, Luigi</creatorcontrib><creatorcontrib>Marchi, Enrica</creatorcontrib><creatorcontrib>Neylon, Ellen</creatorcontrib><creatorcontrib>Johannet, Paul</creatorcontrib><creatorcontrib>Wei, Ying</creatorcontrib><creatorcontrib>Zain, Jasmine</creatorcontrib><creatorcontrib>O'Connor, Owen A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amengual, Jennifer E.</au><au>Clark-Garvey, Sean</au><au>Kalac, Matko</au><au>Scotto, Luigi</au><au>Marchi, Enrica</au><au>Neylon, Ellen</au><au>Johannet, Paul</au><au>Wei, Ying</au><au>Zain, Jasmine</au><au>O'Connor, Owen A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>2013-09-19</date><risdate>2013</risdate><volume>122</volume><issue>12</issue><spage>2104</spage><epage>2113</epage><pages>2104-2113</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Understanding the molecular pathogenesis of lymphoma has led to paradigm-changing treatment opportunities. One example involves tailoring specific agents based on the cell of origin in aggressive lymphomas. Germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL) is known to be driven by an addiction to Bcl6, whereas the activated B-cell (ABC) subtype is driven by nuclear factor κB. In the GC subtype, there is a critical inverse relationship between Bcl6 and p53, the functional status of which is linked to each transcription factor's degree of acetylation. Deacetylation of Bcl6 is required for its transcriptional repressor effects allowing for the oncogene to drive lymphomagenesis. Conversely, acetylation of p53 is activating when class III deacetylases (DACs), or sirtuins, are inhibited by niacinamide. Treatment of DLBCL cell lines with pan-DAC inhibitors in combination with niacinamide produces synergistic cytotoxicity in GC over ABC subtypes. This correlated with acetylation of both Bcl6 and p53. This combination also produced remissions in a spontaneous aggressive B-cell lymphoma mouse model expressing Bcl6. In a phase 1 proof-of-principle clinical trial, 24% of patients with relapsed or refractory lymphoma attained a response to vorinostat and niacinamide, and 57% experienced disease stabilization. We report herein on the preclinical and clinical activity of this targeted strategy in aggressive lymphomas. This trial was registered at www.clinicaltrials.gov as #NCT00691210. •Treatment of DLBCL with the combination of sirtuin and DAC inhibitors leads to synergistic cytotoxicity and acetylation of Bcl6 and p53.•The overall response rate of relapsed lymphoma patients treated with vorinostat and niacinamide was 24%, and an additional 57% achieved stable disease.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23913470</pmid><doi>10.1182/blood-2013-02-485441</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2013-09, Vol.122 (12), p.2104-2113
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2013_02_485441
source ScienceDirect - Connect here FIRST to enable access
subjects Acetylation - drug effects
Adult
Aged
Animals
Cell Line, Tumor
Cell Survival - drug effects
Disease Models, Animal
Drug Evaluation, Preclinical
Drug Synergism
Female
Histone Deacetylase Inhibitors - adverse effects
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylase Inhibitors - therapeutic use
Histone Deacetylases - metabolism
Humans
Inhibitory Concentration 50
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - metabolism
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Mice
Middle Aged
Niacinamide - adverse effects
Niacinamide - pharmacology
Niacinamide - therapeutic use
Proto-Oncogene Proteins - metabolism
Repressor Proteins - metabolism
Sirtuins - metabolism
Treatment Outcome
Tumor Burden - drug effects
Tumor Suppressor Protein p53 - metabolism
Xenograft Model Antitumor Assays
title Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A54%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sirtuin%20and%20pan-class%20I/II%20deacetylase%20(DAC)%20inhibition%20is%20synergistic%20in%20preclinical%20models%20and%20clinical%20studies%20of%20lymphoma&rft.jtitle=Blood&rft.au=Amengual,%20Jennifer%20E.&rft.date=2013-09-19&rft.volume=122&rft.issue=12&rft.spage=2104&rft.epage=2113&rft.pages=2104-2113&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2013-02-485441&rft_dat=%3Cpubmed_cross%3E23913470%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-54be4748bf3661ffda5204008d9fbcf537559ccbffbda8fbd8339c5f6eda52613%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/23913470&rfr_iscdi=true